Drug search by name

Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate and Liver disease

Result of checking the interaction of drug Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate and disease Liver disease for safety when used together.

Check result:

Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Efavirenz is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from efavirenz due to decreased drug clearance. Therapy with efavirenz should be administered cautiously in patients with liver disease. In addition, elevations in serum transaminases to greater than five times the upper limit of normal as well as acute liver failure requiring transplantation have occurred during therapy with efavirenz, most often in patients with a prior history of Hepatitis B and/or C. Monitoring of liver function tests is recommended in these patients.

References:

"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.

Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate

Generic Name: efavirenz / emtricitabine / tenofovir

Brand Name: Atripla

Synonyms: Efavirenz, emtricitabine, and tenofovir

What is Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate?

Another drug Delete

Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

Consumer:

There are no data concerning the use of tenofovir disoproxil fumarate in patients with hepatic impairment. Tenofovir and tenofovir disoproxil are not metabolized by liver enzymes. However, since tenofovir is not entirely eliminated by the kidney (70% to 80%), tenofovir pharmacokinetics may be altered in patients with impaired hepatic function.

References: